/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

CATALYST PHARMACEUTICALS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$22.65 0.0212(2.12%) CPRX at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 22.77
Highest Today 23.24
Today’s Open 22.77
Prev. Close 22.62
52 Week High 26.58
52 Week Low 19.05
Day’s Range: Low 22.77 High 23.24
52-Week Range: Low 19.05 High 26.58
1 day return -
1 Week return -1.4
1 month return +8.15
3 month return +16.62
6 month return -8.7
1 year return +4.98
3 year return +35.88
5 year return +542.89
10 year return -

Institutional Holdings

BlackRock Inc 15.44

Vanguard Group Inc 7.16

iShares Core S&P Small-Cap ETF 5.57

State Street Corp 4.48

Vanguard Total Stock Mkt Idx Inv 2.97

Renaissance Technologies Corp 2.66

Morgan Stanley - Brokerage Accounts 2.60

Deerfield Management Co 2.35

Geode Capital Management, LLC 2.34

iShares Russell 2000 ETF 2.27

Fundsmith LLP 2.21

Smithson Investment Trust Ord 2.21

Goldman Sachs Group Inc 1.97

Bank of America Corp 1.93

Dimensional Fund Advisors, Inc. 1.56

Avantis US Small Cap Value ETF 1.47

American Century Companies Inc 1.44

Royce & Associates, LP 1.29

Charles Schwab Investment Management Inc 1.17

Boston Partners Global Investors, Inc 1.05

Northern Trust Corp 1.04

Vanguard Institutional Extnd Mkt Idx Tr 1.01

Arrowstreet Capital Limited Partnership 1.00

Amvescap Plc. 0.99

SPDR® S&P Biotech ETF 0.95

Fidelity Small Cap Index 0.95

Allianz Asset Management AG 0.85

iShares Russell 2000 Growth ETF 0.83

Qube Research & Technologies 0.83

SPDR® Portfolio S&P 600™ Sm Cap ETF 0.83

iShares S&P Small-Cap 600 Growth ETF 0.81

Vanguard Tax-Managed Small Cap Adm 0.61

Fidelity Extended Market Index 0.50

Pacer US Small Cap Cash Cows 100 ETF 0.47

Kennedy Small Cap Value 0.46

SPDR® S&P 600 Small Cap Growth ETF 0.46

Vanguard Russell 2000 ETF 0.45

Schwab US Small-Cap ETF™ 0.44

Macquarie Small Cap Growth C 0.42

T. Rowe Price Integrated US Sm Gr Eq 0.41

Market Status

Strong Buy: 6

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 2780.28 M

PB Ratio 3.0306

PE Ratio 13.2281

Enterprise Value 2101.88 M

Total Assets 851.41 M

Volume 1036497

Company Financials

Annual Revenue FY23:348393000 348.4M, FY22:214203000 214.2M, FY21:140833000 140.8M, FY20:119072803 119.1M, FY19:102306337 102.3M

Annual Profit FY23:301040000 301.0M, FY22:179810000 179.8M, FY21:118949000 118.9M, FY20:102033646 102.0M, FY19:87547198 87.5M

Annual Net worth FY23:62037000 62.0M, FY22:83079000 83.1M, FY21:39482000 39.5M, FY20:74983000 75.0M, FY19:31875337 31.9M

Quarterly Revenue Q3/2025:148392000 148.4M, Q2/2025:146563000 146.6M, Q1/2025:141421000 141.4M, Q3/2024:128695000 128.7M, Q2/2024:122710000 122.7M

Quarterly Profit Q3/2025:123081000 123.1M, Q2/2025:116605000 116.6M, Q1/2025:123510000 123.5M, Q3/2024:109418000 109.4M, Q2/2024:97961000 98.0M

Quarterly Net worth Q3/2025:52783000 52.8M, Q2/2025:52108000 52.1M, Q1/2025:56737000 56.7M, Q3/2024:43884000 43.9M, Q2/2024:40794000 40.8M

Fund house & investment objective

Company Information Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Organisation Biotechnology

Employees 181

Industry Biotechnology

CEO Mr. Richard John Daly M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow